Aigenpulse Receives ISO 9001:2015 and ISO 27001:2013 Certifications for Quality and Information Security Management

Press release

5th February 2019

Aigenpulse Receives ISO 9001:2015 and ISO 27001:2013 Certification for AI Data Technology

Certification affirms commitment to providing highest standards of quality and information security

Oxford, UK, 4th February 2019: Aigenpulse Ltd., (Aigenpulse), a big data technology company which specialises in structuring, integrating and deriving meaning from large, disparate data assets, today announced it has achieved certification to the internationally recognised standards ISO 9001:2015 and ISO 27001:2013. The independent assessment was conducted by the British Assessment Bureau, a leading certification body, and demonstrates Aigenpulse’s commitment to customer service and product quality (ISO 9001:2015) and in managing information safely and securely (ISO 27001:2013).

ISO accreditation strengthens Aigenpulse’s platform offering, which deploys artificial intelligence (AI) and advanced machine learning technologies to help researchers to unlock the power of their data, ultimately increasing the efficiency at which new and improved drugs reach patients. Scientists use the platform to structure, share and analyse their research, translational and preclinical data. This makes it easier to search and visualise relationships in the large and diverse data sets generated by R&D pipelines. Analyses can be automated, enabling researchers to focus on core science, while benefitting from data to augment experience and intuition in decision making.

Dr. Tobias Kloepper, CEO at Aigenpulse, said: “We are extremely proud of gaining certification to both ISO 9001 and ISO 27001 standards in such a short amount of time – for a company less than three years old, this is a great achievement. These certifications underline our commitment to customers and our focus on quality, data security and reliability.

“As part of implementing a Quality Management System we have automated all of our compliance processes which have been designed to drive high quality performance and continuous improvement. We are now even better placed to respond to customer needs quickly and efficiently.

“Customers, stakeholders and staff can be reassured that their information is being held and managed securely and that as a management team we take our accountability for protecting our systems and client data very seriously.”

ENDS

Notes to Editors:

   Aigenpulse team

For a high res image please contact sarah.jeffery@zymecommunications.com

Contacts:

Aigenpulse contact: Wendy Tindsley, Senior Business Development Manager T: +44 (0) 7807 054617 wendy@aigenpulse.com Press contact: Sarah Jeffery, Zyme Communications T: +44 (0) 7771 730919 sarah.jeffery@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please click here.

About Aigenpulse: www.aigenpulse.com

Aigenpulse is a state-of-the-art software platform focused on accelerating drug discovery by enhancing scientists’ capabilities with advanced data technologies and artificial intelligence.

Scientists use the platform to structure, share and analyse their research, translational and preclinical data. This makes it easier to search and visualise relationships in the large and diverse data sets generated by R&D pipelines – such as genomics, proteomics, biochemical and biophysical assays. Analyses can be automated, enabling researchers to focus on core science, while benefitting from data to augment experience and intuition in decision making.

The Aigenpulse Platform helps biopharma companies to unlock the power of their data, ultimately increasing the efficiency at which new and improved drugs reach patients. Our customers are already gaining deep insights into their operations and research activities, leading them to identify and pursue drug candidates with the highest potential and allowing low potential candidates to fail faster.

Pharma, biotech, CRO and bioinformatics customers are benefitting from the improved traceability, auditability and visibility of progress within their drug discovery and development pipelines. Access to the Aigenpulse platform is via subscription licence agreement and can be integrated into established research processes within weeks. The platform is modular and flexible, and can be rapidly scaled, with integration into existing IT infrastructure, on premises or in the cloud.

Aigenpulse was founded in 2016 and has built a team of expert bioinformaticians, software engineers and project managers with a mission to combine machine learning and human expertise to facilitate the efficient creation of better drugs; making them available to more people.

The company is headquartered in Oxford, UK. 

About British Assessment Bureau www.british-assessment.co.uk

The British Assessment Bureau’s has been providing clients with an award winning service since 1969. In 1997, the Secretary of State for Trade and Industry approved the use of the word ‘British’ in their title, in recognition of their pre-eminent status.

Today, they certify organisations to recognised standards, including ISO 9001 (quality management), ISO 14001 (environmental management), ISO 27001 (information security management) and OHSAS 18001 (occupational health and safety management). Such schemes are based on the establishment of standards, which have been developed to be recognised company-wide, industry-wide, nationally, or internationally.  Their accredited certificates all come with the coveted UKAS ‘Crown &Tick’ underlining the security that only comes from a Government-backed certification.

Contact:

Gabrielle Smith 

Head of Customer and Employee Care 

The British Assessment Bureau

T: +44 (0) 800 404 7007

gabby.smith@british-assessment.co.uk